J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Acorda Therapeutics (ACOR) yesterday. The company’s shares closed yesterday at $16.50, close to its 52-week low of $12.86.
According to TipRanks.com, Kasimov is a 1-star analyst with an average return of -0.4% and a 38.3% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allogene Therapeutics Inc, and Jounce Therapeutics Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Acorda Therapeutics with a $24.17 average price target, which is a 46.5% upside from current levels. In a report issued on December 24, Oppenheimer also maintained a Hold rating on the stock with a $18 price target.
.
See today’s analyst top recommended stocks >>
Based on Acorda Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $13.91 million. In comparison, last year the company had a GAAP net loss of $171 million.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules.
